Modiodal (Modafinil)

Modafinil, the active ingredient in Modiodal, is a eugeroic (wakefulness‑promoting agent) presented as an oral tablet for oral use. It treats excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder in adults.

GNH USA supplies Modiodal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modiodal (modafinil) is used to manage disorders characterized by excessive daytime sleepiness.

- Narcolepsy: reduces daytime sleep attacks and improves wakefulness. - Obstructive sleep apnea (excessive daytime sleepiness): mitigates residual sleepiness when used with standard apnea therapy. - Shift work sleep disorder: helps maintain alertness during scheduled work hours.

Modiodal may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Insomnia: difficulty initiating or maintaining sleep. - Dry mouth: reduced salivary flow.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Psychiatric symptoms: new or worsening anxiety, depression, or hallucinations. - Cardiovascular events: chest pain or arrhythmia in susceptible individuals.

When prescribing Modiodal, clinicians should consider several safety and handling precautions.

- Cardiovascular assessment: evaluate history of hypertension, arrhythmia, or coronary disease. - Psychiatric evaluation: monitor for anxiety, depression, or psychotic symptoms. - Liver function: assess hepatic impairment before initiating therapy. - Drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Modiodal can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase modafinil plasma levels, raising risk of adverse effects. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness by lowering drug concentrations.

Moderate Interactions (Monitor Closely): - Oral contraceptives: modafinil may reduce hormonal efficacy; consider alternative contraception. - Antidepressants (e.g., SSRIs, SNRIs): may increase risk of serotonin syndrome or heightened side effects. - Antihypertensives: possible reduction in blood pressure control; monitor blood pressure.